OUR STORY

2008-2012

R&D of core technologies and pipelines

2012

Toronto Headquarters established in MaRS Discovery District

2013

Chinese Headquarters established in Nanging

Launch the first clinical pan-cancer NGS test for all solid tumors in China

2015

Launch the first clinical pan-cancer NGS test for liquid biopsy samples of cancer patients

Launch of cancer-type specific NGS tests

2016

Launch the first NGS test for MSI and TMB evaluation in cancer

Launch NGS tests for hematological malignancies

Performed 1000+ clinical tests per month

2017

Clinical laboratory certified by CAP

Established central laboratory for CTONG (Chinese Thoracic Oncology Group)

Performed 3000-5000 clinical tests per month

Launch of expansion plan of Toronto Headquarters

2018

Clinical laboratory certified by CLIA

Strategic collaboration with Illumina to develop clinical NGS oncogene kit

NGS-based CDx Kit Essencare® for lung cancer approved by NMPA

Established ultra-sensitive ATG-Seq® technology for liquid biopsy

Performed 8000+ clinical tests per month

2019

Received ISO:13485:2016 certificate for CDx kits manufacturing facility

Performed 10000+ clinical tests per month

International market expansion and research collaborations

Launched ultra-sensitive VANGUARD TM liquid biopsy test for lung cancer

2020

NMPA breakthrough approval for Tumor Mutational Burden CDx kit

A total of 300,000+ clinical tests has been performed

800+ employees